Research and Markets: Celtic Biotech, Ltd. - Product Pipeline Review - 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Global Markets Direct's new company profile "Celtic Biotech, Ltd. - Product Pipeline Review - 2012" to their offering.

Global Markets Direct's pharmaceuticals report, Celtic Biotech, Ltd. - Product Pipeline Review - 2012 provides data on the Celtic Biotech, Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Celtic Biotech, Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from Celtic Biotech, Ltd. and industry-specific third party sources, put together by Global Markets Direct's team.


- Celtic Biotech, Ltd. - Brief Celtic Biotech, Ltd. overview including business description, key information and facts, and its locations and subsidiaries.

- Review of current pipeline of Celtic Biotech, Ltd. human therapeutic division.

- Overview of pipeline therapeutics across various therapy areas.

- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.

- Product profiles for late stage and clinical stage products of Celtic Biotech, Ltd. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.

- Recent updates of the Celtic Biotech, Ltd.'s pipeline in the last quarter.

- Key discontinued and dormant projects.

- Latest news and deals relating to the products.

Reasons to Buy:

- Evaluate Celtic Biotech, Ltd.'s strategic position with total access to detailed information on its product pipeline.

- Assess the growth potential of Celtic Biotech, Ltd. in its therapy areas of focus.

- Identify new drug targets and therapeutic classes in the Celtic Biotech, Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.

- Exploit collaboration and partnership opportunities with Celtic Biotech, Ltd..

- Avoid Intellectual Property Rights related issues.

- Explore the dormant and discontinued projects of Celtic Biotech, Ltd. and identify potential opportunities in those areas.

For more information visit

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source: Research and Markets